Who
Mark Wilterding
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, RxSight.
In numbers
- Trades disclosed
- 20
- Buys
- 0
- Sells
- 1
- Bought
- $0
- Sold
- $108K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 12 Jan 2026
- Last trade
- 5 Sep 2026
- Last filed
- 9 Sep 2026
Companies traded
Activity over time
1 Aug – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 5 Sep 2026filed 9 Sep 2026 | RXST RxSightoption or derivative · Medical Devices | SEC FORM 4 Code D | —258,770 | filing |
| 5 Sep 2026filed 9 Sep 2026 | RXST RxSightoption or derivative · Medical Devices | SEC FORM 4 Code A | —258,770 | filing |
| 5 Sep 2026filed 9 Sep 2026 | RXST RxSightoption or derivative · Medical Devices | SEC FORM 4 Code D | —258,770 | filing |
| 5 Sep 2026filed 9 Sep 2026 | RXST RxSightoption or derivative · Medical Devices | SEC FORM 4 Code A | —258,770 | filing |
| 2 Sep 2026filed 2 Sep 2026 | RXST RxSightMedical Devices | SEC FORM 4 Sold | $54K7,765 at $6.96 | filing |
| 2 Sep 2026filed 2 Sep 2026 | RXST RxSightMedical Devices | SEC FORM 4 Sold | $54K7,765 at $6.96 | filing |
| 31 Aug 2026filed 2 Sep 2026 | RXST RxSightMedical Devices | SEC FORM 4 Code M | —20,441 | filing |
| 31 Aug 2026filed 2 Sep 2026 | RXST RxSightoption or derivative · Medical Devices | SEC FORM 4 Code M | —20,441 at $0.00 | filing |
| 31 Aug 2026filed 2 Sep 2026 | RXST RxSightoption or derivative · Medical Devices | SEC FORM 4 Code M | —20,441 at $0.00 | filing |
| 31 Aug 2026filed 2 Sep 2026 | RXST RxSightMedical Devices | SEC FORM 4 Code M | —20,441 | filing |
| 28 Feb 2026filed 3 Mar 2026 | RXST RxSightMedical Devices | SEC FORM 4 Code M | —20,441 | filing |
| 28 Feb 2026filed 3 Mar 2026 | RXST RxSightMedical Devices | SEC FORM 4 Code F | $61K8,068 at $7.61 | filing |
| 28 Feb 2026filed 3 Mar 2026 | RXST RxSightoption or derivative · Medical Devices | SEC FORM 4 Code M | —20,441 at $0.00 | filing |
| 28 Feb 2026filed 3 Mar 2026 | RXST RxSightoption or derivative · Medical Devices | SEC FORM 4 Code M | —20,441 at $0.00 | filing |
| 28 Feb 2026filed 3 Mar 2026 | RXST RxSightMedical Devices | SEC FORM 4 Code M | —20,441 | filing |
| 28 Feb 2026filed 3 Mar 2026 | RXST RxSightMedical Devices | SEC FORM 4 Code F | $61K8,068 at $7.61 | filing |
| 12 Jan 2026filed 30 Jan 2026 | RXST RxSightoption or derivative · Medical Devices | SEC FORM 4 Code A | —258,770 at $0.00 | filing |
| 12 Jan 2026filed 30 Jan 2026 | RXST RxSightoption or derivative · Medical Devices | SEC FORM 4 Code A | —163,528 at $0.00 | filing |
| 12 Jan 2026filed 30 Jan 2026 | RXST RxSightoption or derivative · Medical Devices | SEC FORM 4 Code A | —258,770 at $0.00 | filing |
| 12 Jan 2026filed 30 Jan 2026 | RXST RxSightoption or derivative · Medical Devices | SEC FORM 4 Code A | —163,528 at $0.00 | filing |
News
RxSight Reports Inducement Grants as Permitted by the Nasdaq Listing RulesRXST · manilatimes.net · 24 Oct 2026RxSight Appoints Eye Care Industry Leaders to Drive Commercial TransformationRXST · manilatimes.net · 19 Oct 2026RxSight (NASDAQ:RXST) vs. Coloplast A/S (OTCMKTS:CLPBY) Head to Head AnalysisRXST · tickerreport.com · 14 Oct 2026
0 headlines in the last 90 days name Mark Wilterding; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.